WO2020171285A1 - 대기오염물질에 의한 피부 손상 방지 및 항노화용 펩타이드와 이의 용도 - Google Patents
대기오염물질에 의한 피부 손상 방지 및 항노화용 펩타이드와 이의 용도 Download PDFInfo
- Publication number
- WO2020171285A1 WO2020171285A1 PCT/KR2019/004881 KR2019004881W WO2020171285A1 WO 2020171285 A1 WO2020171285 A1 WO 2020171285A1 KR 2019004881 W KR2019004881 W KR 2019004881W WO 2020171285 A1 WO2020171285 A1 WO 2020171285A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- skin
- aging
- contaminants
- cells
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 182
- 230000037380 skin damage Effects 0.000 title claims abstract description 27
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 25
- 239000000809 air pollutant Substances 0.000 title description 7
- 231100001243 air pollutant Toxicity 0.000 title description 7
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 claims abstract description 49
- 239000000203 mixture Substances 0.000 claims abstract description 41
- 230000000694 effects Effects 0.000 claims abstract description 40
- 230000009759 skin aging Effects 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 239000002537 cosmetic Substances 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 19
- 239000000428 dust Substances 0.000 claims abstract description 11
- 239000000779 smoke Substances 0.000 claims abstract description 9
- 241000208125 Nicotiana Species 0.000 claims abstract description 6
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 5
- 201000011510 cancer Diseases 0.000 claims abstract description 5
- 230000006872 improvement Effects 0.000 claims abstract description 5
- 239000000356 contaminant Substances 0.000 claims description 69
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 50
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 22
- 230000037303 wrinkles Effects 0.000 claims description 17
- 230000006378 damage Effects 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 208000012239 Developmental disease Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 208000017443 reproductive system disease Diseases 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 206010013786 Dry skin Diseases 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000010247 contact dermatitis Diseases 0.000 claims description 2
- 230000037336 dry skin Effects 0.000 claims description 2
- 210000003372 endocrine gland Anatomy 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 230000007688 immunotoxicity Effects 0.000 claims description 2
- 231100000386 immunotoxicity Toxicity 0.000 claims description 2
- 231100000225 lethality Toxicity 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 230000004199 lung function Effects 0.000 claims description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 54
- 108090000623 proteins and genes Proteins 0.000 abstract description 45
- 210000003491 skin Anatomy 0.000 abstract description 33
- 210000004927 skin cell Anatomy 0.000 abstract description 31
- 239000003344 environmental pollutant Substances 0.000 abstract description 18
- 231100000719 pollutant Toxicity 0.000 abstract description 17
- 208000019693 Lung disease Diseases 0.000 abstract description 3
- 208000017520 skin disease Diseases 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000001153 anti-wrinkle effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 107
- 230000001965 increasing effect Effects 0.000 description 38
- 230000032683 aging Effects 0.000 description 33
- 239000012887 cigarette smoke extract Substances 0.000 description 30
- 239000013618 particulate matter Substances 0.000 description 30
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 description 26
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 25
- 230000002401 inhibitory effect Effects 0.000 description 23
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 22
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 22
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 21
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 21
- 102000008186 Collagen Human genes 0.000 description 18
- 108010035532 Collagen Proteins 0.000 description 18
- 229920001436 collagen Polymers 0.000 description 18
- 238000001262 western blot Methods 0.000 description 17
- 108010014258 Elastin Proteins 0.000 description 16
- 102000016359 Fibronectins Human genes 0.000 description 16
- 108010067306 Fibronectins Proteins 0.000 description 16
- 108010074918 Cytochrome P-450 CYP1A1 Proteins 0.000 description 15
- 102100031476 Cytochrome P450 1A1 Human genes 0.000 description 15
- 108010041191 Sirtuin 1 Proteins 0.000 description 15
- 238000012790 confirmation Methods 0.000 description 13
- 238000003757 reverse transcription PCR Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 206010051246 Photodermatosis Diseases 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- 230000008845 photoaging Effects 0.000 description 12
- 239000004017 serum-free culture medium Substances 0.000 description 12
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 11
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 10
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 10
- -1 blockers Substances 0.000 description 10
- 230000004941 influx Effects 0.000 description 10
- 102000016942 Elastin Human genes 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229920002549 elastin Polymers 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 108090000991 Aquaporin 3 Proteins 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- 238000001179 sorption measurement Methods 0.000 description 8
- 101150008656 COL1A1 gene Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000002510 keratinocyte Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 6
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 6
- 230000005754 cellular signaling Effects 0.000 description 6
- 235000019504 cigarettes Nutrition 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 102000004363 Aquaporin 3 Human genes 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 102000007999 Nuclear Proteins Human genes 0.000 description 5
- 108010089610 Nuclear Proteins Proteins 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 238000003915 air pollution Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000010094 cellular senescence Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 102000034240 fibrous proteins Human genes 0.000 description 3
- 108091005899 fibrous proteins Proteins 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000002676 xenobiotic agent Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 2
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 2
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 101710145505 Fiber protein Proteins 0.000 description 2
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 2
- 101150024767 arnT gene Proteins 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000032677 cell aging Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 150000002013 dioxins Chemical class 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 102000034285 signal transducing proteins Human genes 0.000 description 2
- 108091006024 signal transducing proteins Proteins 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- VGGGRWRBGXENKI-UHFFFAOYSA-N 1-chlorodibenzo-p-dioxin Chemical compound O1C2=CC=CC=C2OC2=C1C=CC=C2Cl VGGGRWRBGXENKI-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000008056 Aryl Hydrocarbon Receptor Nuclear Translocator Human genes 0.000 description 1
- 108010049386 Aryl Hydrocarbon Receptor Nuclear Translocator Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 238000007804 gelatin zymography Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000008810 intracellular oxidative stress Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000036558 skin tension Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008280 toxic mechanism Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 238000007805 zymography Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Definitions
- the present invention relates to a novel peptide having an anti-aging effect and an activity for preventing skin damage by contaminants, and a use thereof.
- Air pollutants have the greatest effect on the respiratory tract among the internal organs of the human body, but the skin with the largest surface area in direct contact with pollutants and continuous exposure is one of the organs that are the main targets of pollutants.
- the problem of skin health deterioration caused by the external environment has been focused on problems caused by ultraviolet rays contained in sunlight, but due to the increasingly deteriorating air pollution problem and the increase of pollutants in the air, studies are no longer relevant.
- the aryl hydrocarbon receptor is a key receptor that plays a role in inducing skin damage by transmitting harmful signals within cells when air pollutants contact the skin.
- 2,3,7,8-tetra Dioxins such as chlorodibenzo-p-dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD) and polyaromatic hydrocarbons (PAHs) are bound to the AhR when exposed to the human skin Thus, it moves to the cell nucleus, like the mechanism of action of steroid hormones, and causes a toxic mechanism.
- the dioxin complex bound to AhR binds to the Arnt (AhR nuclear translocator) protein present in the nucleus, and the AhR/Arnt complex is a transcriptional regulatory region of the target gene including Cytochrome P450s (P450 or cyps; CYP1A1, CYP1A2, and CYP1B1). It binds to a nucleotide sequence called DRE or XRE (drug/xenobiotic responsive element) in induces the transcription of several gene groups, resulting in toxicity.
- DRE drug/xenobiotic responsive element
- skin cells may undergo aging due to various causes, and wrinkles may occur due to aging of skin cells. It can be divided into chronological aging (intrinsic aging), which is a natural aging that appears over time according to biological processes, and degenerative change occurring in the area exposed to sunlight, and photoaging (photosensitive aging) in which the chronological aging is combined. I can. When the expression or activity of various factors related to cell growth is inhibited, natural cell aging may occur, and photoaging of skin cells may proceed by light of 280 nm to 400 nm wavelength contained in sunlight.
- chronological aging intrinsic aging
- photoaging photosensitive aging
- UVB ultraviolet rays
- UVB having a wavelength in the range of 280 nm to 320 nm
- damage to the skin or fibers may occur, and a soot phenomenon may occur in which the skin burns black.
- UVB When UVB is irradiated, the accumulation of ROS and free radicals in skin cells is promoted, and by stimulating the intracellular signaling system by radicals, it can induce oxidative stress on biomolecules such as DNA, proteins, and lipids. Damage may occur.
- An object of the present invention is to provide a peptide that can be used to protect skin cells by preventing skin damage caused by pollutants by inhibiting the influx of contaminants such as dioxin, fine dust, cigarette smoke, and the like.
- an object of the present invention is to provide a peptide that can be used to reduce the aging phenomenon of skin cells that occurs naturally or is caused by ultraviolet rays of sunlight, thereby improving skin wrinkles.
- an object of the present invention is to provide a pharmaceutical composition capable of preventing or treating diseases caused by contaminants or improving skin aging, including the above peptide as an active ingredient.
- an object of the present invention is to provide a cosmetic composition capable of preventing skin damage by contaminants and improving skin aging by including the above peptide as an active ingredient.
- one aspect of the present invention provides a peptide for preventing skin damage by contaminants, comprising the amino acid sequence of SEQ ID NO: 1.
- Another aspect of the invention provides a skin anti-aging peptide comprising the amino acid sequence of SEQ ID NO: 1.
- Another aspect of the present invention provides a pharmaceutical composition for preventing or treating diseases caused by contaminants, comprising the amino acid sequence of SEQ ID NO: 1.
- Another aspect of the present invention provides a pharmaceutical composition for improving skin aging, comprising the amino acid sequence of SEQ ID NO: 1.
- Another aspect of the present invention provides a cosmetic composition for preventing skin damage due to contaminants or improving skin aging, containing a peptide comprising the amino acid sequence of SEQ ID NO: 1 as an active ingredient.
- the peptides provided by the present invention prevent the influx of pollutants such as dioxin, fine dust, cigarette smoke, etc. existing in the air into the cells, and suppress the aging phenomenon of skin cells, so cancer and skin that can be caused by pollutants It can be usefully used as an active ingredient in a pharmaceutical composition that prevents or treats diseases, lung diseases, or improves skin aging, and can be used as an active ingredient in a cosmetic composition to protect the skin from contaminants and to improve skin aging and wrinkles. It can have an effect.
- pollutants such as dioxin, fine dust, cigarette smoke, etc.
- 1A to 1C are Western blotting results showing the amount of AhR nuclear transfer when treated with TCDD, PM, and CSE, respectively, for HaCaT cells treated with the peptide containing the amino acid sequence of SEQ ID NO: 1.
- Con means control
- NC means negative control.
- 1D is a Western blotting result showing the amount of AhR nuclear transfer when CSE was treated with respect to A549 cells treated with a peptide containing the amino acid sequence of SEQ ID NO: 1.
- 2A to 2C are RT-PCR results showing the expression levels of CYP1A1 and COX-2 genes when treated with TCDD, PM, and CSE, respectively, for HaCaT cells treated with a peptide containing the amino acid sequence of SEQ ID NO: 1. to be.
- 3A and 3B are Western blotting results showing the amount of proteins of MMP-1 and COX-2 when treated with TCDD and PM, respectively, for HaCaT cells treated with a peptide containing the amino acid sequence of SEQ ID NO: 1. .
- 4A and 4B are photographs confirming whether the peptide containing the amino acid sequence of SEQ ID NO: 1 is precipitated by adsorption with PM and CSE, respectively.
- 5A is a Western blotting result showing the amount of p-Akt and p-ERK proteins of HaCaT cells treated with a peptide containing the amino acid sequence of SEQ ID NO: 1.
- 5B is an RT-PCR result showing the expression level of the SIRT1 gene in HaCaT cells treated with a peptide containing the amino acid sequence of SEQ ID NO: 1.
- 6A is a Western blotting result showing the amount of p-Akt and p-ERK proteins in NIH3T3 cells treated with a peptide containing the amino acid sequence of SEQ ID NO: 1.
- 6B is an RT-PCR result showing the expression levels of collagen (Col1a1), fibronectin, and elastin genes in NIH3T3 cells treated with a peptide containing the amino acid sequence of SEQ ID NO: 1.
- FIG. 7 is an RT-PCR result showing the expression levels of SIRT1 and AQP3 genes in HaCaT cells irradiated with UVB and treated with a peptide containing the amino acid sequence of SEQ ID NO: 1.
- 8A is an RT-PCR result showing the expression levels of collagen (Col1a1), fibronectin, and elastin genes of NIH3T3 cells irradiated with UVB and treated with a peptide containing the amino acid sequence of SEQ ID NO: 1. .
- Figure 8b is a gelatin character showing the result of Western blotting showing the amount of MMP-1 protein in NIH3T3 cells treated with a peptide containing the amino acid sequence of SEQ ID NO: 1 by UVB irradiation and confirming the amount of MMP-2 protein This is the result of the emography.
- One aspect of the present invention provides a novel peptide capable of preventing skin damage caused by contaminants.
- Another aspect of the present invention provides a novel peptide capable of inhibiting skin aging.
- the peptide refers to a polymer consisting of two or more amino acids linked by a peptide bond.
- the peptide itself is too large to effectively enter the target tissue or cell, or has a short half-life and thus disappears in the body in a short period of time.
- the peptide is composed of 20 or less, for example, 15 or less, or 10 or less amino acids, which have the activity of inhibiting cell entry of contaminants.
- the peptide of the present invention may include the amino acid sequence of SEQ ID NO: 1, and within a range that does not affect the skin damage inhibitory activity and anti-aging activity of the skin by contaminants of the peptide, deletion, insertion, and It may be variants or fragments of amino acids having different sequences by substitution or a combination thereof.
- Amino acid exchange at the peptide level that does not totally alter the skin damage inhibitory activity and the anti-aging activity of the skin by contaminants of the peptide is known in the art. In some cases, it may be modified by phosphorylation, sulfation, acrylation, glycosylation, methylation, and farnesylation.
- the present invention includes a peptide comprising an amino acid sequence substantially identical to that of a peptide comprising the amino acid sequence of SEQ ID NO: 1, and a variant thereof or an active fragment thereof.
- the substantially identical protein refers to an amino acid sequence having 75% or more, for example, 80% or more, 90% or more, 95% or more, sequence homology with the amino acid sequence of SEQ ID NO: 1.
- the peptide may additionally include a targeting sequence, a tag, a labeled residue, a half-life, or an amino acid sequence prepared for a specific purpose to increase the stability of the peptide.
- the peptide of the present invention can be obtained by various methods well known in the art.
- it may be prepared by using a polynucleotide recombination and protein expression system, or by a method for in vitro synthesis through chemical synthesis such as peptide synthesis, and a cell-free protein synthesis method.
- the N-terminus of the peptide or A protecting group may be attached to the C-terminus.
- the protecting group may be an acetyl group, a fluorenyl methoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, or a polyethylene glycol (PEG), but it is possible to modify the peptide, especially to improve the stability of the peptide. If there is an ingredient, it can be included without limitation.
- The'stability' means not only stability in vivo that protects the peptide of the present invention from attack by protein cleavage enzymes in vivo, but also storage stability (eg, room temperature storage stability).
- the contaminant of the present invention may be dioxin (TCDD), particulate matter (PM), or cigarette smoke extract (CSE), but is not limited thereto. It can contain any xenobiotics that are toxic that can interfere with the growth and normal metabolic processes of the body. Prevention of skin damage by contaminants can be achieved by preventing contaminants from entering the cell, thereby making it impossible for the contaminants to be toxic within the cells.
- TCDD dioxin
- PM particulate matter
- CSE cigarette smoke extract
- the peptide of the present invention may inhibit the inflow of contaminants into cells through adsorption with the contaminants.
- contaminants such as dioxins enter the cell, they can bind to AhR to induce expression of several gene groups, and accordingly, expression of CYP1A1, CYP1A2, CYP1B1, COX-2, MMPs, etc. may increase.
- CYP1A1, CYP1A2, CYP1B1, COX-2, MMPs, etc. may increase.
- By checking the change in the expression level of the genes as described above it is possible to confirm the cytoprotective effect of the peptide of the present invention by inhibiting the inflow of the contaminant into the cell.
- the skin anti-aging of the present invention means an effect of inhibiting the aging phenomenon of skin cells.
- the aging may be aging that occurs naturally in cells over time, may be photoaging caused by sunlight, and in particular, may be photoaging caused by ultraviolet rays.
- the aging may be induced by intracellular oxidative stress phenomena that may be caused by various causes, thereby inhibiting cell growth or apoptosis, and inhibiting the synthesis of various fibrous proteins constituting it in skin cells. And the expression of degrading enzymes can be increased.
- genes such as SIRT1, AQP3, Col1a1, fibronectin, and elastin are suppressed in skin cells by UV irradiation, and the expression of MMP-1 and MMP-2 genes is promoted, which can cause photoaging and wrinkles in skin cells.
- the peptides of the present invention may increase the expression of genes in pathways related to cell proliferation in skin cells, increase the expression of a fiber protein synthesis gene, or induce the suppression of the expression of a fiber proteolytic gene. Therefore, the peptide can improve the wrinkles and elasticity of the skin by increasing the synthesis of fibrous protein, and has anti-aging activity of the skin by improving the skin barrier.
- Anti-aging and skin of the peptide of the present invention by confirming the expression level of a protein related to cell proliferation, an anti-aging gene, a fiber protein, and a gene related to its degrading enzyme whose expression level changes as the skin aging progresses. You can check the wrinkle improvement effect.
- dioxin and fine dust together with a peptide containing the amino acid sequence of SEQ ID NO: 1 in keratinocytes and fibroblasts .
- the tobacco smoke extract As a result of confirming the amount of nuclear transfer of AhR, the expression level of CYP1A1, COX-2 and MMP-1, the inflow of contaminants such as the dioxin, fine dust, and tobacco smoke extract into the cell is suppressed, It was confirmed that the amount of nuclear transfer of AhR and the amount of expression of CYP1A1, COX-2, and MMP-1 according to the influx of contaminants decreased depending on the peptide treatment of the present invention (see FIGS. 1A to 3B).
- fine dust and tobacco smoke extract are mixed with the peptide containing the amino acid sequence of SEQ ID NO: 1 of the present invention.
- the peptide of the present invention was precipitated by adsorption with contaminants such as the fine dust and tobacco smoke extract, and it was confirmed that adsorption occurred depending on the amount of the peptide (see FIGS. 4A and 4B). .
- keratinocytes and fibroblasts are treated with a peptide containing the amino acid sequence of SEQ ID NO: 1, and phosphorylation
- Akt and ERK in the form of Akt, the amount of expression of SIRT1, collagen, fibronectin, and elastin, the amount of phosphorylated Akt, ERK, the amount of SIRT1 protein, and the amount of fibroproteins such as collagen, fibronectin, and elastin It was confirmed that the increase was dependent on the peptide treatment of the present invention (see FIGS. 5A to 6B).
- the amino acid sequence of SEQ ID NO: 1 is used in keratinocytes and fibroblasts.
- the peptide of the present invention prevents skin damage by inhibiting the inflow of contaminants such as TCDD, PM, and CSE into the cell, and inhibits the expression of genes related to photoaging caused by natural aging of skin cells or ultraviolet rays. It is clear that it has the activity of improving the wrinkles of the skin through anti-aging activity by controlling it, and therefore, the peptide of the present invention is an active ingredient of a composition for preventing skin damage by contaminants, anti-aging and improving skin wrinkles. It can be useful.
- Another aspect of the present invention provides a pharmaceutical composition for preventing or treating diseases caused by contaminants containing a peptide comprising the amino acid sequence of SEQ ID NO: 1 as an active ingredient.
- Another aspect of the present invention provides a pharmaceutical composition for improving skin aging containing a peptide comprising the amino acid sequence of SEQ ID NO: 1 as an active ingredient.
- the peptide comprising the amino acid sequence of SEQ ID NO: 1 is the '1. It is the same as the peptide described in the section'Peptides for cell protection against contaminants or anti-aging skin cells'. 'Peptides for cell protection against contaminants or anti-aging of skin cells' are used, and hereinafter, only the configuration specific to a pharmaceutical composition for preventing or treating diseases caused by contaminants and improving skin aging will be described.
- the peptide of the present invention has the effect of inhibiting the influx of contaminants into cells and inhibiting aging of skin cells, and the pharmaceutical composition containing the peptide as an active ingredient prevents diseases caused by contaminants or It can be used for therapeutic purposes, and it can be used for improving aging of skin cells to reduce wrinkles and improve skin elasticity.
- Diseases caused by the pollutants refer to diseases that can be caused by pollutants such as dioxin, fine dust, and air pollutants such as cigarette smoke, skin diseases, lung diseases, nervous system diseases, reproductive system diseases, cardiovascular disease.
- pollutants such as dioxin, fine dust, and air pollutants
- pollutants such as cigarette smoke, skin diseases, lung diseases, nervous system diseases, reproductive system diseases, cardiovascular disease.
- related diseases including cancer, atopic dermatitis, contact dermatitis, seborrheic dermatitis, acne, dry skin, psoriasis, lethality, immunotoxicity, peripheral nervous system damage, central nervous system damage, endocrine gland abnormalities, reproductive system disorders, infants and toddlers.
- Developmental disorders anemia, bronchitis, emphysema, reduced lung function, asthma, chronic branchitis, arrhythmia, heart attack, angina, or myocardial infarction.
- the pharmaceutical composition of the present invention prevents the occurrence of diseases caused by the pollutants by inhibiting the influx of pollutants into cells, or alleviates symptoms by inhibiting the pollutants additionally introduced into the cells of the patient of the disease. , It can be used for treating diseases by inhibiting the worsening of the condition.
- the skin aging refers to a negative change in the skin condition that can be caused by natural aging or photoaging of skin cells, and reduces wrinkles, fine lines, skin elasticity and/or tension, thinning, thinning of the skin, It may be physiological and/or actinic aging such as decreased gloss and gloss, and external skin degradation due to aging such as deterioration of the dermis due to exposure to ultraviolet rays, and especially collagen fibers. have.
- the pharmaceutical composition of the present invention restores a medically good skin condition, such as returning the skin elasticity to a normal level in relation to the skin aging caused by natural or light by inhibiting the aging phenomenon that may occur in the skin cells. It can be used to improve skin aging.
- the pharmaceutical composition containing the peptide of the present invention as an active ingredient is a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person having ordinary skill in the art. It may be prepared in a unit dosage form by formulation using or may be prepared by incorporating it into a multi-dose container.
- the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet, capsule or gel (e.g., hydrogel), and may additionally include a dispersant or a stabilizer. have.
- the peptides included in the pharmaceutical composition may be transported in a pharmaceutically acceptable carrier such as colloidal suspension, powder, saline, lipids, liposomes, microspheres, or nano spherical particles. They can be complexed or associated with a vehicle and are known in the art such as lipids, liposomes, microparticles, gold, nanoparticles, polymers, condensation reagents, polysaccharides, polyamino acids, dendrimers, saponins, adsorption enhancing substances or fatty acids. It can be delivered in vivo using known delivery systems.
- a pharmaceutically acceptable carrier such as colloidal suspension, powder, saline, lipids, liposomes, microspheres, or nano spherical particles. They can be complexed or associated with a vehicle and are known in the art such as lipids, liposomes, microparticles, gold, nanoparticles, polymers, condensation reagents, polysaccharides, polyamin
- pharmaceutically acceptable carriers include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia, rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, which are commonly used in formulation.
- a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like may be additionally included in addition to the above components.
- the pharmaceutical composition according to the present invention can be administered orally or parenterally during clinical administration, and can be used in the form of a general pharmaceutical formulation. That is, the pharmaceutical composition of the present invention can be administered in various oral and parenteral dosage forms at the time of actual clinical administration, but when formulated, diluents such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc. Or it is formulated using excipients.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient, such as starch, calcium carbonate, sucrose, or It is prepared by mixing lactose and gelatin.
- Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, syrups, etc.
- various excipients such as wetting agents, sweetening agents, fragrances, and preservatives may be included.
- Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories.
- Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as the non-aqueous solvent and the suspension.
- injectable esters such as ethyl oleate
- Witepsol, Macrogol, Tween 61, cacao butter, laurin, glycerol, gelatin, and the like can be used as a base for suppositories.
- the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
- the'pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type of disease, severity, drug activity, Sensitivity to drugs, time of administration, route of administration and rate of excretion, duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field.
- the pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent, or may be administered in combination with a therapeutic agent for a disease caused by other contaminants or a therapeutic agent for improving skin aging, and simultaneously, separately, or sequentially with the conventional therapeutic agent. Can be administered, single or multiple administration. It is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all the above factors, and this can be easily determined by a person skilled in the art.
- the effective amount of the pharmaceutical composition of the present invention may vary depending on the patient's age, sex, condition, weight, absorption of the active ingredient in the body, inactivation rate, excretion rate, type of disease, and drugs used in combination, and the route of administration, Obesity may be increased or decreased according to the severity, sex, weight, age, etc.
- the peptide of the present invention may be administered from about 0.0001 ⁇ g to 500 mg, such as 0.01 ⁇ g to 100 mg, per 1 kg of the patient's body weight per day.
- it may be dividedly administered several times a day, for example, 2 to 3 times a day at regular time intervals.
- Another aspect of the present invention provides a cosmetic composition for preventing skin damage or improving skin aging by contaminants containing a peptide comprising the amino acid sequence of SEQ ID NO: 1 as an active ingredient.
- the peptide comprising the amino acid sequence of SEQ ID NO: 1 is the '1. It is the same as the peptide described in the section'Peptides for cell protection against contaminants or anti-aging skin cells'. 'Peptides for cell protection against contaminants or anti-aging of skin cells' are used, and hereinafter, only the unique composition of the cosmetic composition for preventing skin damage or improving skin aging caused by contaminants will be described.
- the peptide of the present invention has the effect of inhibiting the influx of contaminants into cells and inhibiting aging of skin cells, and the cosmetic composition containing the peptide as an active ingredient prevents skin damage that may be caused by contaminants. It can be used for the purpose of improving the aging of skin cells, reducing wrinkles and improving the elasticity of the skin.
- the peptide may be contained in 0.001 to 30% by weight of the total 100% by weight of the cosmetic composition, for example, 0.1 to 20% by weight, 0.1 to 10% by weight, 1 to 10% by weight, or 2 to 5% by weight. , But is not limited thereto.
- the cosmetic composition containing the peptide of the present invention as an active ingredient may have a synergistic effect on the activity of the peptide, for example, within a range that does not affect the cell influx of contaminants of the peptide and the activity of improving aging of skin cells. It may further contain other ingredients that may have characteristics that may be.
- fatty substances for example, fatty substances, organic solvents, solubilizing agents, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, Cosmetics such as fillers, sequestering and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, fragrances, hydrophilic or lipophilic actives, lipid vesicles or any other ingredients commonly used in cosmetics, etc. Or, it may contain an adjuvant commonly used in the field of dermatology, and the ingredients may be contained in an amount generally used in the field of cosmetics or dermatology.
- the cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, gels, lotions, essences, creams, powders, soaps, shampoos, rinses, It can be formulated with cosmetics such as pack mask, surfactant-containing cleansing, cleansing foam, cleansing water, oil, liquid foundation, cream foundation or spray.
- cosmetics such as pack mask, surfactant-containing cleansing, cleansing foam, cleansing water, oil, liquid foundation, cream foundation or spray.
- a solvent, a solubilizing agent or an emulsifying agent may be used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan can be used.
- a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, aluminum metahydroxy Seeds, microcrystalline cellulose, bentonite, agar or tracant, and the like may be used.
- a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, aluminum metahydroxy Seeds, microcrystalline cellulose, bentonite, agar or tracant, and the like
- the formulation is a cream or gel, wax, paraffin, tracant, animal oil, starch, cellulose derivatives, silicone, bentonite, polyethylene glycol, silica, zinc oxide or talc may be used as a carrier component.
- a propellant such as silica, talc, aluminum hydroxy group, lactose, calcium silicate, chlorofluorohydrocarbon, propane/butane, or dimethyl ether may be included as a carrier component.
- the formulation is a surfactant-containing cleansing
- aliphatic alcohol sulfate aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, imidazolinium derivative, isethionate, methyltaurate, sarcosinate, fatty acid amide ether sulfate , Aliphatic alcohols, alkylamidobetaines, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters, and the like may be used.
- dioxin hereinafter referred to as'TCDD'
- particulate matter hereinafter referred to as'PM'
- cigarette smoke extract hereinafter referred to as'CSE'
- AhR aryl hydrocarbon receptor
- HaCaT cells human keratinocyte
- TCDD, PM, and CSE were treated with TCDD, PM, and CSE, respectively
- A549 cells human alveolar epithelial cells
- TCDD, PM, and CSE were mixed with the peptides of the present invention and reacted for 1 hour on serum-free media before use.
- the experimental process in the case of treatment with PM and CSE was also carried out in the same manner as in the case of treatment with TCDD, PM was treated with a concentration of 50 ⁇ g/cm 2 and CSE with a concentration of 2%, respectively.
- the CSE was prepared by filling 50 ml of PBS into a vacuum flask and connecting the flask to a vacuum pump to burn 40 cigarettes.
- the experiment confirmed by treatment with CSE on A549 cells (human alveolar epithelial cells) is also similar to the above experimental procedure. After seeding 48 passages of A549 cells in a 6-well plate at a cell density of 5 ⁇ 10 5 /well, CSE Western blotting was performed on the nuclear protein separated by treatment.
- TCDD, PM, and CSE were treated on HaCaT cells, and then the expression levels of CYP1A1 and COX-2 were confirmed.
- AhR acts as a transcription factor and increases the expression of CYP1A1 and COX-2. Therefore, by checking how much genes of CYP1A1 and COX-2 are expressed, the It is possible to check the degree of inflow into the cell and whether or not AhR is active.
- TCDD, PM, and CSE were mixed with the peptides of the present invention and reacted for 1 hour on serum-free media before use.
- RNA was reverse transcribed into cDNA, and RT-PCR was performed using the primers (Table 2) of CYP1A1 and COX-2 (cDNA polymerization kit and PCR pre-mix: Intron, Korea).
- GAPDH primers used for comparison of the total amount of RNA in each treatment group were those having the sequence shown in Table 2 below.
- the experimental process in the case of treatment with PM and CSE was also carried out in the same manner as in the case of treatment with TCDD, PM was treated with a concentration of 25 ⁇ g/cm 2 and CSE with a concentration of 2%, respectively.
- the CSE was prepared by filling 50 ml of PBS into a vacuum flask and connecting the flask to a vacuum pump to burn 40 cigarettes.
- Sequence number Sequence name Base sequence 2 CYP1A1 forward 5'- GGATCTTTCTCTGTACCCTGG -3' 3 CYP1A1 reverse 5'- AGCATGTCCTTCAGCCCAGA -3' 4 COX-2 forward 5'- ATCATTCACCAGGCAAATTGC -3' 5 COX-2 reverse 5'- GGCTTCAGCATAAAGCGTTTG -3' 6 GAPDH forward 5'- GGTGTGAACGGATTTGGCCGTATTG -3' 7 GAPDH reverse 5'- CCGTTGAATTTGCCGTGAGTGGAGT -3'
- TCDD and PM were treated on HaCaT cells, and then the amounts of MMP-1 and COX-2 proteins were confirmed.
- the MMP-1 is a collagen-degrading enzyme, and when the activity of AhR is promoted by contaminants such as TCDD, AhR acts as a transcription factor to increase the expression of MMP-1 and COX-2, so MMP-1, COX-2 By checking how much of the gene is expressed, the degree of inflow of the contaminants into the cell and the activity of AhR can be confirmed.
- TCDD and PM were mixed with the peptides of the present invention and reacted for 1 hour in serum-free media before use.
- MMP-1 and COX were used using an anti-MMP-1 antibody (cell signaling, USA) and an anti-COX-2 antibody (Santacruz biotechnology, USA). Western blotting was performed on -2.
- -Actin is anti- to compare the total amount of protein used in the experiment. -It was confirmed using an actin antibody (Santacruz biotechnology, USA).
- the precipitation pattern of the peptide and contaminant mixture was observed with the naked eye.
- the peptide containing the amino acid sequence of SEQ ID NO: 1 has the effect of trapping and adsorbing contaminant molecules such as PM and CSE, thereby inhibiting the inflow of the contaminant molecules into the skin. I can.
- the amount of protein and gene expression related to natural aging were confirmed.
- Akt and ERK are proteins involved in the signal transduction process related to cell proliferation, and exhibit activity in phosphorylated forms (p-Akt and p-ERK, respectively).
- p-Akt and p-ERK phosphorylated forms
- 81 passages of HaCaT cells were seeded in a 6-well plate at a cell concentration of 3 ⁇ 10 5 /well, and then cultured in serum free media for 24 hours, and then the peptides of the present invention were at a concentration of 10, 50, and 100 ⁇ M, respectively. Treated for 15 minutes. Positive control was treated with growth factors of bFGF 100 nM and IGF 100 nM instead of the peptide. After the cells were reacted with the mixture for 15 minutes, a lysate was obtained from the cells, and p-Akt and p were obtained using an anti-p-Akt antibody (cell signaling, USA) and an anti-p-ERK antibody (cell signaling, USA). Western blotting for -ERK was performed.
- -Actin is anti- to compare the total amount of protein used in the experiment. -It was confirmed using an actin antibody (Santacruz biotechnology, USA).
- the degree of phosphorylation of Akt and ERK in HaCaT cells is increased by the peptide containing the amino acid sequence of SEQ ID NO: 1, which means that the growth of cells is promoted. It can be seen that it can suppress the natural aging phenomenon.
- the amounts of proteins and genes related to natural aging were checked.
- Akt and ERK are proteins involved in the signal transduction process related to cell proliferation, and exhibit activity in phosphorylated forms (p-Akt and p-ERK, respectively).
- p-Akt and p-ERK phosphorylated forms
- NIH3T3 cells (mouse fibroblast) were seeded in a 6-well plate at a cell density of 3 ⁇ 10 5 /well, and then cultured with serum free media for 24 hours, and then the peptides of the present invention were respectively 10, 50, Treatment was performed for 15 minutes at a concentration of 100 ⁇ M. Positive control was treated with 50 nM of growth factors bFGF and 25 nM of IGF instead of the peptide. After the cells were reacted with the mixture for 15 minutes, a lysate was obtained from the cells, and p-Akt and p were obtained using an anti-p-Akt antibody (cell signaling, USA) and an anti-p-ERK antibody (cell signaling, USA). Western blotting for -ERK was performed. -Actin is anti- to compare the total amount of protein used in the experiment. -It was confirmed using an actin antibody (Santacruz biotechnology, USA).
- the degree of phosphorylation of Akt and ERK in NIH3T3 cells is increased by the peptide containing the amino acid sequence of SEQ ID NO: 1, which means that cell growth is promoted. It can be seen that it can suppress the natural aging phenomenon.
- COL1A1 is a gene encoding collagen I.
- NIH3T3 cells 34 passages of NIH3T3 cells were seeded in a 6-well plate at a cell density of 5 ⁇ 10 5 /well, and then cultured with serum-free media for 16 hours, and then the peptides of the present invention were at a concentration of 10, 50, and 100 ⁇ M, respectively. Treated with for 1 hour. After washing with PBS and filling with PBS, UVA of 6 J/cm 2 was previously irradiated 1 hour before. And again, the peptides of the present invention were each treated at the above concentration for 6 hours. Positive control was treated with NaC 2.5 mM and Quercetin 50 ⁇ M instead of the peptide.
- MMP-1 and MMP-2 which encode proteins related to collagen degradation, are increased by irradiation with ultraviolet rays.
- the peptide of the present invention is treated, the synthesis of the MMP-1 and MMP-2 proteins is inhibited again, resulting in cell It was confirmed whether it can suppress the aging phenomenon.
- NIH3T3 cells 31 passages of NIH3T3 cells were seeded in a 6-well plate at a cell density of 5 ⁇ 10 5 /well, and then cultured in serum free media for 16 hours, and then the peptides of the present invention were added at concentrations of 10, 50 and 100 ⁇ M, respectively. Treated for hours. After washing with PBS and filling with PBS, UVB of 6 J/cm 2 was irradiated 1 hour ago. And again, the peptides of the present invention were each treated at the above concentration for 48 hours. Positive control was treated with NaC 2.5 mM and Quercetin 50 ⁇ M instead of the peptide.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
서열번호 | 펩타이드 서열 |
1 | SYSGVLFFLK |
서열번호 | 서열 이름 | 염기서열 |
2 | CYP1A1 forward | 5'- GGATCTTTCTCTGTACCCTGG -3' |
3 | CYP1A1 reverse | 5'- AGCATGTCCTTCAGCCCAGA -3' |
4 | COX-2 forward | 5'- ATCATTCACCAGGCAAATTGC -3' |
5 | COX-2 reverse | 5'- GGCTTCAGCATAAAGCGTTTG -3' |
6 | GAPDH forward | 5'- GGTGTGAACGGATTTGGCCGTATTG -3' |
7 | GAPDH reverse | 5'- CCGTTGAATTTGCCGTGAGTGGAGT -3' |
서열번호 | 서열 이름 | 염기서열 |
8 | SIRT1 forward | 5'- TCAGTGGCTGGAACAGTGAG -3' |
9 | SIRT1 reverse | 5'- TCTGGCATGTCCCACTATCA -3' |
서열번호 | 서열 이름 | 염기서열 |
16 | AQP3 forward | 5'- CCTTCTTGGGTGCTGGAATA -3' |
17 | AQP3 reverse | 5'- ACACGATAAGGGAGGCTCTG -3' |
Claims (12)
- 서열번호 1의 아미노산 서열을 포함하는, 오염물질에 의한 피부 손상 방지용 펩타이드.
- 청구항 1에 있어서,상기 펩타이드는 오염물질의 피부 내 유입 억제 활성을 갖는 것인, 오염물질에 의한 피부 손상 방지용 펩타이드.
- 청구항 1에 있어서,상기 펩타이드는 오염물질과 흡착하는 것인, 오염물질에 의한 피부 손상 방지용 펩타이드.
- 청구항 1 내지 청구항 3 중 어느 한 항에 있어서,상기 오염물질은 다이옥신, 미세먼지 및 담배연기 추출물로 이루어진 군으로부터 선택되는 것인, 오염물질에 의한 피부 손상 방지용 펩타이드.
- 서열번호 1의 아미노산 서열을 포함하는, 피부 항노화용 펩타이드.
- 청구항 5에 있어서,상기 피부 항노화는 피부의 주름 또는 탄력의 개선인, 피부 항노화용 펩타이드.
- 청구항 1의 펩타이드를 유효성분으로 함유하는, 오염물질에 의해 유발되는 질환의 예방 또는 치료용 약학적 조성물.
- 청구항 7에 있어서,상기 오염물질에 의해 유발되는 질환은 암, 아토피 피부염, 접촉성 피부염, 지루성 피부염, 여드름, 피부건조증, 건선, 치사, 면역 독성, 말초 신경계 손상, 중추 신경계 손상, 내분비선 이상, 생식기관 장애, 영아 및 유아의 발달 장애, 빈혈, 기관지염, 폐기종, 폐기능 감소, 천식, 만성지관지염, 부정맥, 심장마비, 협심증, 및 심근경색증으로 구성된 군으로부터 선택되는 어느 하나 이상인, 오염물질에 의해 유발되는 질환의 예방 또는 치료용 약학적 조성물.
- 청구항 5의 펩타이드를 유효성분으로 함유하는, 피부 노화 개선용 약학적 조성물.
- 청구항 9에 있어서,상기 피부 노화 개선은 주름의 개선인, 피부 노화 개선용 약학적 조성물.
- 청구항 1 또는 청구항 5의 펩타이드 중 어느 하나를 유효성분으로 함유하는, 오염물질에 의한 피부 손상 방지 또는 피부 노화 개선용 화장료 조성물.
- 청구항 11에 있어서,상기 화장료 조성물은 용액, 현탁액, 유탁액, 겔, 로션, 에센스, 크림, 파우더, 비누, 샴푸, 린스, 팩마스크, 계면활성제-함유 클렌징, 클렌징 폼, 클렌징 워터, 오일, 리퀴드 파운데이션, 크림 파운데이션, 및 스프레이로 이루어진 군으로부터 선택되는 1종의 제형을 갖는 것인, 오염물질에 의한 피부 손상 방지 또는 피부 노화 개선용 화장료 조성물.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/059,909 US11433013B2 (en) | 2019-02-20 | 2019-04-23 | Peptide for preventing skin damage caused by air pollutants and for anti-aging, and use thereof |
JP2020567020A JP7048766B2 (ja) | 2019-02-20 | 2019-04-23 | 大気汚染物質による皮膚損傷防止用及び抗老化用のペプチド、並びにその用途 |
CN201980037621.8A CN112236441B (zh) | 2019-02-20 | 2019-04-23 | 大气污染物质导致的皮肤损伤防止及抗老化用肽及其用途 |
BR112021016104A BR112021016104A2 (pt) | 2019-02-20 | 2019-04-23 | Peptídeo para prevenir danos à pele causados por poluentes do ar e para antienvelhecimento, e uso do mesmo |
EP19916142.3A EP3904369A4 (en) | 2019-02-20 | 2019-04-23 | PEPTIDE FOR THE PREVENTION OF SKIN DAMAGE CAUSED BY ATMOSPHERIC POLLUTANTS AND FOR THE FIGHT AGAINST AGING, AND USE IN RELATION |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190020013A KR102065171B1 (ko) | 2019-02-20 | 2019-02-20 | 대기오염물질에 의한 피부 손상 방지 및 항노화용 펩타이드와 이의 용도 |
KR10-2019-0020013 | 2019-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020171285A1 true WO2020171285A1 (ko) | 2020-08-27 |
Family
ID=69153102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/004881 WO2020171285A1 (ko) | 2019-02-20 | 2019-04-23 | 대기오염물질에 의한 피부 손상 방지 및 항노화용 펩타이드와 이의 용도 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11433013B2 (ko) |
EP (1) | EP3904369A4 (ko) |
JP (1) | JP7048766B2 (ko) |
KR (1) | KR102065171B1 (ko) |
CN (1) | CN112236441B (ko) |
BR (1) | BR112021016104A2 (ko) |
WO (1) | WO2020171285A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220072348A (ko) * | 2020-11-25 | 2022-06-02 | (주)케어젠 | 미세먼지에 의한 세포 손상 방지 활성을 갖는 펩타이드 및 이의 용도 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102539445B1 (ko) | 2020-11-25 | 2023-06-05 | (주)케어젠 | 미세먼지에 의한 세포 손상 방지 활성을 갖는 펩타이드 및 이의 용도 |
KR20230046141A (ko) * | 2021-09-29 | 2023-04-05 | (주)케어젠 | 항노화 활성을 갖는 펩타이드 및 이의 용도 |
KR20230046140A (ko) * | 2021-09-29 | 2023-04-05 | (주)케어젠 | 항노화 활성을 갖는 펩타이드 및 이의 용도 |
KR20230046872A (ko) * | 2021-09-30 | 2023-04-06 | (주)케어젠 | 항노화 활성을 갖는 펩타이드 및 이의 용도 |
KR20230046873A (ko) * | 2021-09-30 | 2023-04-06 | (주)케어젠 | 항노화 활성을 갖는 펩타이드 및 이의 용도 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100136103A1 (en) * | 2007-05-08 | 2010-06-03 | Tupperware Products S.A. | Cosmetic anti-ageing skin care compositions |
KR101092915B1 (ko) * | 2009-07-10 | 2011-12-12 | (주)케어젠 | 성장인자―유래 펩타이드 및 이의 용도 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1585482A4 (en) | 2002-09-25 | 2009-09-09 | Genentech Inc | NEW COMPOSITIONS AND METHODS FOR TREATING PSORIASIS |
FR2873698B1 (fr) * | 2004-07-29 | 2006-10-20 | D Anjou Sa Lab | Nouveau peptide et composition pharmaceutique le contenant |
ES2358829B1 (es) | 2009-10-23 | 2012-06-25 | Lipotec, S.A. | Péptidos útiles en el tratamiento y/o cuidado de la piel, mucosas y/o cabello y su uso en composiciones cosméticas o farmacéuticas. |
JP6925805B2 (ja) | 2014-10-31 | 2021-08-25 | 京都府公立大学法人 | ラミニンによる角膜の新規治療 |
KR101744959B1 (ko) * | 2014-12-05 | 2017-06-12 | (주)케어젠 | 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
WO2016164216A1 (en) * | 2015-04-09 | 2016-10-13 | Isp Investments Inc. | Method of cosmetic treatment to protect the skin from pollution and improve skin regeneration |
US11220669B2 (en) | 2015-06-05 | 2022-01-11 | Amolifescience Co., Ltd. | Defined three dimensional microenvironment for cell culture |
US11085056B2 (en) | 2015-08-28 | 2021-08-10 | Molecular Transfer, Inc. | Transfection complexes and methods of using the same |
WO2017151733A1 (en) * | 2016-03-01 | 2017-09-08 | Molecular Transfer, Inc. | Plant virus movement proteins and methods of using the same |
KR101889322B1 (ko) * | 2016-08-17 | 2018-08-20 | (주)진셀팜 | 주름 개선 및 항노화 효과를 가지는 펩타이드, 및 이의 용도 |
JP2020500009A (ja) * | 2016-10-21 | 2020-01-09 | ベスタロン コーポレイション | 切断可能ペプチドならびにそれを含む殺虫性タンパク質及び殺線虫性タンパク質 |
US20190382719A1 (en) * | 2016-12-07 | 2019-12-19 | Amolifescience Co., Ltd. | Three-dimensional micro-environment structure for controlling cell behavior, three-dimensional surface for controlling cell behavior, and method for manufacturing array and three-dimensional micro-environment structure |
KR101943083B1 (ko) * | 2017-03-30 | 2019-01-29 | (주)케어젠 | 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도 |
-
2019
- 2019-02-20 KR KR1020190020013A patent/KR102065171B1/ko active IP Right Grant
- 2019-04-23 BR BR112021016104A patent/BR112021016104A2/pt unknown
- 2019-04-23 EP EP19916142.3A patent/EP3904369A4/en active Pending
- 2019-04-23 US US17/059,909 patent/US11433013B2/en active Active
- 2019-04-23 WO PCT/KR2019/004881 patent/WO2020171285A1/ko unknown
- 2019-04-23 CN CN201980037621.8A patent/CN112236441B/zh active Active
- 2019-04-23 JP JP2020567020A patent/JP7048766B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100136103A1 (en) * | 2007-05-08 | 2010-06-03 | Tupperware Products S.A. | Cosmetic anti-ageing skin care compositions |
KR101092915B1 (ko) * | 2009-07-10 | 2011-12-12 | (주)케어젠 | 성장인자―유래 펩타이드 및 이의 용도 |
Non-Patent Citations (4)
Title |
---|
DATABASE Protein 16 September 2010 (2010-09-16), DOI,M., THYBOLL,J., KORTESMAA,J., JANSSON,K., IIVANAINEN,A., PARVARDEH,M., TIMPL,R.: "laminin alpha5 chain precursor [Homo sapiens]", XP055733053, retrieved from NCBI Database accession no. AAM12527.1 * |
DATABASE Protein 20 March 2018 (2018-03-20), "laminin subunit alpha-5 isoform X1 [Pan troglodytes]", XP055733207, retrieved from NCBI Database accession no. XP_024207819.1 * |
DATABASE Protein 23 March 2015 (2015-03-23), VENTER, J. C. AND ADAMS,M.D., MYERS,E.W., LI,P.W., MURAL,R.J., SUTTON,G.G., SMITH,H.O., YANDELL,M., EVANS,C.A.: "laminin, alpha 5, isoform CRA_b [Homo sapiens]", XP055732947, retrieved from NCBI Database accession no. EAW75373.1 * |
See also references of EP3904369A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220072348A (ko) * | 2020-11-25 | 2022-06-02 | (주)케어젠 | 미세먼지에 의한 세포 손상 방지 활성을 갖는 펩타이드 및 이의 용도 |
KR102474470B1 (ko) | 2020-11-25 | 2022-12-07 | (주)케어젠 | 미세먼지에 의한 세포 손상 방지 활성을 갖는 펩타이드 및 이의 용도 |
Also Published As
Publication number | Publication date |
---|---|
CN112236441A (zh) | 2021-01-15 |
JP7048766B2 (ja) | 2022-04-05 |
CN112236441B (zh) | 2023-12-05 |
EP3904369A4 (en) | 2022-11-23 |
US20210205200A1 (en) | 2021-07-08 |
KR102065171B1 (ko) | 2020-01-13 |
JP2021526145A (ja) | 2021-09-30 |
EP3904369A1 (en) | 2021-11-03 |
BR112021016104A2 (pt) | 2021-11-09 |
US11433013B2 (en) | 2022-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020171285A1 (ko) | 대기오염물질에 의한 피부 손상 방지 및 항노화용 펩타이드와 이의 용도 | |
WO2021033829A1 (ko) | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 | |
WO2017155232A2 (ko) | 발모 촉진 활성 및/또는 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도 | |
WO2018182172A1 (ko) | 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도 | |
WO2020218781A1 (ko) | 불멸화 줄기세포 유래 엑소좀 풍부 배양액 및 장미꽃봉오리 추출물을 유효성분으로 포함하는 기능성 조성물 | |
WO2017200288A1 (ko) | 천연 한방 추출물을 유효성분으로 포함하는 미백, 피부 노화 방지 또는 피부 주름 개선용 조성물 | |
WO2023055007A1 (ko) | 항노화 활성을 갖는 펩타이드 및 이의 용도 | |
WO2023054817A1 (ko) | 항노화 활성을 갖는 펩타이드 및 이의 용도 | |
WO2017119756A1 (ko) | 주름개선, 노화방지, 미백, 항염증 기능성 신규 펩티드 및 이를 포함하는 조성물 | |
WO2018111042A2 (ko) | 한약재 추출물을 유효성분으로 포함하는 화장료 조성물 | |
WO2020138674A1 (ko) | 근육 이완용 조성물 | |
RU2773534C1 (ru) | Пептид для профилактики повреждений кожи, вызванных атмосферными загрязнениями, и для омолаживающей терапии, а также его использование | |
WO2023055006A1 (ko) | 항노화 활성을 갖는 펩타이드 및 이의 용도 | |
WO2023127986A1 (ko) | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 | |
WO2024106585A1 (ko) | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 | |
WO2023127985A1 (ko) | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 | |
WO2023055010A1 (ko) | 항노화 활성을 갖는 펩타이드 및 이의 용도 | |
WO2023127984A1 (ko) | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 | |
WO2019088648A1 (ko) | 미도드린을 포함하는 조성물 및 이의 용도 | |
WO2024106588A1 (ko) | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 | |
WO2023055011A1 (ko) | 항노화 활성을 갖는 펩타이드 및 이의 용도 | |
WO2024106587A1 (ko) | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 | |
WO2023055051A1 (ko) | 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도 | |
WO2023127987A1 (ko) | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 | |
WO2023055060A1 (ko) | 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19916142 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020567020 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019916142 Country of ref document: EP Effective date: 20210728 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021016104 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112021016104 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210813 |